HIV-associated lipodystrophy syndrome: Assessment and management

Journal of Infection

Volumn 46, Issue 2, 2003, Pages 87-93

  Bodasing, N ^a   Fox, R ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; EFAVIRENZ; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTIC ACID; LAMIVUDINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NEVIRAPINE; PIOGLITAZONE; PRAVASTATIN; PROTEINASE INHIBITOR; RECOMBINANT GROWTH HORMONE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; SAQUINAVIR; SIMVASTATIN; SULFONYLUREA; TESTOSTERONE; THYROID HORMONE; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ZIDOVUDINE;

ALCOHOL CONSUMPTION; ANTHROPOMETRY; APPETITE; BODY COMPOSITION; BODY HEIGHT; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; DIET THERAPY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FAMILY HISTORY; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; IMPEDANCE; LIPODYSTROPHY; LIVER FUNCTION TEST; MEDICAL ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL STATUS; PATIENT CARE; PATIENT MONITORING; PHYSIOTHERAPY; PLASTIC SURGERY; REVIEW; RISK ASSESSMENT; SELF EVALUATION; SOCIAL PSYCHOLOGY; THYROID FUNCTION TEST; WASTING SYNDROME;

EID: 0037323116     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2002.1103     Document Type: Review

References (57)

1. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351: 1328.
2. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999; 131: 548.
3. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351: 1959.
4. Mary-Krause M, Cotte L, Partisani M, Simon A. Impact of treatment with protease inhibitors (PI) on myocardial infarction (MI) occurrence in HIV-infected men. Programs and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, Illinois. Abstract 657.
5. Klein D, Hurley L, Sorel M, Sidney S. Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients? Programs and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, Illinois. Abstract 655.
6. Maggi P, Serio G, Epifani G et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14: F123-F128.
7. Wilkie S, Chan R, Lees R, Sullivan D, Grinspoon S. Increased carotid intima-media thickness in women with HIV lipodystrophy. Antiviral Ther 2001; 6: 82-83.
8. Stein JH, Klein MA, Bellehumeur JL et al. Use of human immuno-deficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257-262.
9. Chambless LE, Heiss G, Folsom AR et al. Association of coronary heart disease incidence with carotid artery wall thickness and major risk factors: the atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997; 146: 483-494.
10. Grunfeld C. Dyslipidaeimia due to HIV infection and its therapy. Antiviral Ther 1999; 4: 11-13.
11. Lungdren JD. Perspective of HIV-associated coronary heart disease. Program and Abstracts of the XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain. Abstract WeOr203.
12. Dassopoulos T, Ehrenpreis E. Acute pancreatitis in human immunodeficiency-infected patents: a review. Am J Med 1999; 107(1): 78-84.
13. Meyer D, Behrens G, Schmidt RE, Stoll M. Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors. AIDS 1999; 13: 1147-1148.
14. Johns DG, Gill MJ. Avascular necrosis in HIV infection. AIDS 1999; 13: 1997-1998.
15. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read 2000; 10: 546-550.
16. Bodasing N, Petrie J, Pithie A, Fox R. Measuring insulin sensitivity in HIV-infected patients using the hyperinsulinaemic euglycaemic clamp technique. HIV Med 2002; 1(3): 184.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
18. Haq IU, Ramsay L, Jackson PR, Wallis EJ. Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods. Q J Med 1999; 92(7): 379-385.
19. Moyle G, Baldwin C, Phillpot M. Managing metabolic disturbances and lipodystrophy: diet, excurses and smoking advice. AIDS Read 2001; 11: 589-592.
20. Grinspoon S, Corcoran C, Parlman K, Costello M, Rosenthal D, Anderson E et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomised, controlled trial. Ann Intern Med 2000; 133: 348-355.
21. Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996; 125: 873-882.
22. Schwarz JM, Mulligan K, Lee J et al. Effects of recombinant human growth hormone on hepatic liver and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrin Metab 2002; 87: 942.
23. Aubron-Olivier C et al. Benefit of polylactic acid implant (New Fill) in severe facial lipoatrophy in HIV infected patients: preliminary results of the Vega Study. 8th Conference on Clinical Aspects and Treatment of HIV Infection, October 2001, Athens, Greece. Abstract 020.
24. Serra M. Facial implants with polymethyl-methylcrylate for lipodystrophy correction: 30 months follow up. Antiviral Ther 2001; 6(4): 75.
25. Del Pino V, Arevalo JM, Moreno S, Dronda F. Successful surgical therapy with polyvinyl gel microspheres of severe facial lipoatrophy: results after one year of follow up. Antiviral Ther 2001; 6(4): 74.
26. Ponce-de-Leon S, Iglesias M, Ceballos J, Ostrosky-Zeichner L. Liposuction for protease-inhibitor-associated lipodystrophy. Lancet 1999; 353: 1244.
27. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998; 352: 1031-1032.
28. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1-34.
29. Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16: 569-577.
30. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000; 14: 807-812.
31. Ruiz L, Negredo E, Domingo P et al. The Spanish Lipodystrophy Group. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immun Def Syndr 2001; 27(3): 229-236.
32. Martinez E, Conget I, Lozano L et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13(7): 805-810.
33. Martinez E, Garcia-Viejo MA, Blanco JL et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000; 31: 1266-1273.
34. Bonnet E, Lepec R, Bluteau M. Evolution of lipodystrophy syndrome and lipidic profile in HIV patients after switching from protease inhibitors to efavirenz. 7th Conference on Retroviruses and Opportunistic Infection, January 30-February 2, 2000, San Francisco.Abstract 49.
35. Blanco F, Casimiro C, Gomez F et al. Metabolic outcome in HIV-positive patients after switching PI to NNRTI. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto 2000. Abstract P83.
36. Rozenbaum W, Delfraissy J, Bentata M, De Truchis P, Antoun Z. Improvement of Lipodystrophy in HIV-1 infected subjects switching from 2NRTI/PI to 2NRTI/Abacavir. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000, San Francisco. Abstract 47.
37. Carr A, Workman C, Smith DE et al. Mitochondrial Toxicity (MITOX) Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288(2): 207-215.
38. Walli RK, Michl GM, Bogner JR, Goebel FD. Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res 2001; 6(10): 413-421.
39. Lafeuillade A. Comparison of the metabolic disorders and clinical lipodystrophy 48 weeks after switching from highly active antiretroviral therapy to TRIZIVIR versus continued highly active antiretroviral therapy. (TRIZAL: AZL30002). Antiviral Ther 2001; 6(Suppl. 4): 20-21.
40. John M, James I, McKinnon E et al. A randomised, controlled, open-label study of revision of anti-retroviral regimens containing stavudine (d4T) and/or a protease inhibitor (PI) to zidovudine (ZDV)/lamivudine (3TC)/abacavir (ABC) to prevent or reverse lipoatrophy: 48-week data. Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle. Absract 701-T.
41. McComsey G, Lonergan T, Fisher R et al. Improvements in lipoatrophy (LA) are observed after 24 weeks when stavudine (d4T) is replaced by either abacavir (ABC) or zidovudine (ZDV). Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle. Absract 701-T.
42. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999; 13: 1000-1002.
43. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000; 284: 472-477.
44. Arioglu E, Duncan-Morin J, Sebring N et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133: 263-274.
45. Calmy A, Hirschel B, Karsegaard L et al. A pilot study for the use of pioglitazone in the treatment of highly active antiretroviral therapy lipodystrophy syndromes. Antiviral Ther 2001; 6(Suppl. 4): 32-33.
46. Visnegarwala F, Maldonado MR. Use of PPRA-(gamma) modulator rosiglitazone in normoglycaemic patients with HIV-lipodystrophy syndrome. Antiviral Ther 2002; 6(Suppl. 4): 82.
47. John M, Mallal S. Hyperlactaema syndromes in people with HIV infection. Curr Opinion Infect Dis 2002; 15: 23-29.
48. Brinkman K. Management of hyperlactaemia: no need for routine lactate measurements. AIDS 2001; 15: 795-797.
49. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 1998; 352: 291-292.
50. Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. AIDS 1997; 11: 1294-1296.
51. Famularo G, Moretti S, Marcellini S et al. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with with antiretroviral nucleoside analogues. AIDS 1997; 11: 185-190.
52. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-1115.
53. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-2099.
54. Clasey JL, Hartman ML, Kanaley J et al. Body composition by DEXA in older adults: accuracy and influence of scan mode. Med Sci Sports Exerc 1997; 29: 560-567.
55. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351: 871-875.
56. Burn P, Comitis S, Moyle G. Comparison of Abdominal Fat Distribution in HIV +ve patients with and without clinical fat redistribution and HIV -ve patients, using computerised tomography. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000, San Francisco. Abstract 22.
57. Muurahainen N. Detection of occult wasting by BIA technology. In: Programs and Abstracts of the X International Conference on AIDS 1994; 10(2): Abstract PB0895.